B. Wautlet

发表

Identification of CDK4 Sequences Involved in Cyclin D1 and p16 Binding*

K. G. Coleman, K. Webster, S. A. Sedman, 1997, The Journal of Biological Chemistry.

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.

J. Fargnoli, S. Sheriff, A. Mathur, 2020, ACS medicinal chemistry letters.

Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.

J. Fargnoli, S. Sheriff, B. Fink, 2018, ACS medicinal chemistry letters.

The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases

J. Fargnoli, J. Barrish, J. Hunt, 2010, Molecular Cancer Therapeutics.

Ketamine-induced locomotion in rats in an open-field

B. Wautlet, B. E. Hetzler, 1985, Pharmacology Biochemistry and Behavior.

Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.

J. Fargnoli, J. Barrish, J. Tokarski, 2005, Journal of medicinal chemistry.

Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

Punit Marathe, Ravindra Tejwani, Arvind Mathur, 2008, Bioorganic & medicinal chemistry letters.

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)

J. Fargnoli, G. Derbin, J. Barrish, 2008, Journal of medicinal chemistry.

Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.

J. Fargnoli, J. Tokarski, G. Trainor, 2010, Bioorganic & medicinal chemistry letters.

Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase.

David S. Nirschl, David S Nirschl, J. Fargnoli, 2008, Bioorganic & medicinal chemistry letters.

Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGF beta RI).

Amol G. Dikundwar, J. Fargnoli, S. Sheriff, 2018 .

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.

J. Fargnoli, J. Hunt, B. Fink, 2004, Journal of medicinal chemistry.

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.

J. Fargnoli, J. Tokarski, G. Trainor, 2009, Journal of medicinal chemistry.

Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.

J. Fargnoli, J. Tokarski, D. Xie, 2008, Journal of medicinal chemistry.

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

J. Fargnoli, G. Derbin, J. Barrish, 2006, Journal of medicinal chemistry.

Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.

J. Fargnoli, J. Tokarski, J. Hunt, 2005, Bioorganic & medicinal chemistry letters.

Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.

W. Humphreys, J. Tokarski, L. Leith, 2000, Journal of medicinal chemistry.

Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGFβRI).

Amol G. Dikundwar, J. Fargnoli, S. Sheriff, 2018, Bioorganic & medicinal chemistry.

Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.

J. Fargnoli, G. Derbin, J. Barrish, 2006, Journal of medicinal chemistry.

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.

J. Fargnoli, J. Tokarski, G. Trainor, 2009, Journal of medicinal chemistry.

Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

J. Fargnoli, G. Derbin, J. Barrish, 2008, Bioorganic & medicinal chemistry letters.

Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.

J. Fargnoli, J. Tokarski, J. Hunt, 2008, Bioorganic & medicinal chemistry letters.